The REACH legislation for chemicals risk assessment 1 looks set to have a big impact on the numbers of laboratory animals that will be needed for tests to fill data gaps that exist for some 30,000 or so existing chemicals. However, this impact could be substantially reduced, if increasing demands to make maximum use of alternative testing methods were sincerely acted upon. As some 70% of the testing required will be for reproductive toxicity (potentially involving as many as 10,000 or so existing chemicals), 2 this is a controversial issue among regulators, scientists and animal welfare and protection groups. 3 There is pressure from some quarters to base testing on traditional animal approaches, 4 and in particular, via the two-generation test for reproductive toxicity in the rat. However, such a test is labour-intensive and requires large numbers of animals, and, in addition, it might sometimes be necessary to conduct further tests in a second species, such as the rabbit. This strategy compromises both animal welfare and the achievement of the main objective of the REACH system -to protect the public from exposure to possibly harmful existing chemicals, within a sensible time-frame. It is important that, in the ongoing EC REACH Implementation Project (RIP) meetings, an objective view of the potential of alternatives to contribute to toxicity testing is available to, and understood by, all the experts involved.
The need to resort to in vivo testing for reproductive toxicity should be alleviated by the existence of three in vitro embyrotoxicity assays (the Micromass test, the Whole Embryo Culture test and the Embryonic Stem Cell test), which have been formally validated and recommended as screening tests for reproductive toxicity testing. 5 However, these tests have yet to be accepted by regulatory authorities, and no OECD Health Effects Test Guidelines (TGs) exist for them at present. Following their validation, there were high hopes that one or more of these tests would provide the basis for a non-animal test battery for screening for chemicals that were specifically toxic to the fetus and/or the embryo, some of which might act as teratogens, as was recommended by the ECVAM Scientific Advisory Committee (ESAC) following its peer review of the validation study. 6 The predictive performance of the tests was deemed to be generally satisfactory, although it was recognised that they were most suitable for distinguishing between strong and weak embryotoxins.
In view of the above, and because only some 1% of the 2000 or so known animal teratogens are active in humans, 7 it is legitimate to ask why there is still much interest in basing reproductive toxicity testing for the REACH system on the traditional in vivo methods. This issue is best addressed by asking the following questions, which require satisfactory and publicly-available answers from those responsible for the implementation of the REACH system: 6. What would be the best way to cope with the large amount of reproductive toxicity testing that will be required by the REACH system, and could the data from in vitro tests be used for quantitative risk assessment?
With respect to Question 1, a number of serious reservations concerning the three in vitro embryotoxicity tests were discussed at a second ECVAM workshop on reproductive toxicity, held in 2003, on which a report has only recently been published. 8 These concerns were: a) their relevance to a wide diversity of chemical classes (given that there were only 20 chemicals in the test set; and the number of developmental toxicity mechanisms giving rise to the endpoints scored was limited); b) the lack of a biotransformation system to detect indirect acting agents; and c) the relationships between the effects seen in vitro and what might occur in vivo. The ECVAM report presents a very negative viewpoint concerning the practical implementation of the three embryotoxicity tests. As a result, the situation regarding the regulatory use of the three embryotoxicity assays is somewhat confused, and further action of one kind or another is urgently needed. In my opinion, none of the above concerns is a legitimate basis for precluding the usage of the embryotoxicity tests for screening. It is unlikely that they would show unacceptably high levels of false negative data with a larger range of chemicals, a trait that would be a serious drawback for any screening test. In addition, their overall predictivity, particularly for strong embryotoxins, was high, and there is no reason why such a result should not be obtained for a larger number of chemicals. So, a positive result in any one of the in vitro embryotoxicity assays would enable a decision to be made as to whether to undertake further testing, to withdraw the chemical from use for certain purposes, or to classify and label it as a reproductive toxin.
Many other non-animal tests for reproductive toxicity (Question 2) exist. 9 However, although none of them has been validated, they might provide useful information, particularly if a negative result was obtained in one or more of the validated embryotoxicity tests. Clearly, under such circumstances, it would be necessary to conduct further testing, since there are several reasons for believing that the embryotoxicity tests would be liable to produce false negatives.
The necessity to use a two-generation reproductive toxicity test (Question 3) has been controversial for some time, and has been raised yet again in a recent ATLA editorial. 2 This perceived need is based on: a) the importance of identifying any chronic adverse effects of substances; and b) the possibility that effects could be seen in later generations, due to the transmission of germ-line mutations induced in the dams originally exposed. However, the long-term exposure of the general population to many industrial chemicals is most unlikely. Reproductive effects due to mutation can be detected by conventional short-term in vivo genotoxicity testing. However, the probability that a defect would become visible in the second generation is no more likely than that it would become apparent in the third or any subsequent generation. Thus, the gain from undertaking a two-generation test is outweighed by its disadvantages.
Furthermore, in 117 two-generation studies on pharmaceutical agents, there were only two cases of specific effects being seen in the second generation. 10 Cooper et al. 11 also found that, in more than 350 twogeneration studies on pesticide chemicals, there were only two exceptions to the conclusion that an F2 generation was not necessary. In addition, there is no substantial evidence to prove that there is a correlation between the adverse effects observed in twogeneration studies in rodents and adverse effects on human reproduction and fertility. 12 This raises the possibility that the routine use of two-generation (OECD TG 416) studies could be replaced by an enhanced one-generation study. 2, 8 The suggested enhancements are: a) extending the chemical dosing and observation periods; and b) conducting more-stringent clinical and post-mortem checks on the animals. The adoption of these enhancements would lead to the detection of a wider range of adverse effects on reproduction and development, without the need for a two-generation test, but with a concomitant substantial reduction in animal numbers. Bergfelt and Timm 13 of the US EPA have recently proposed to the OECD an in vivo alternative (the Life-Stages F1-Extended One-Generation Reproductive Toxicity Test) to the twogeneration test, which would also take account of toxicity elicited by endocrine disruptors.
In common with others, I have previously advocated the use of OECD TG 421 (Reproductive/ Developmental screening study) prior to a two-generation study, and following in vitro screening (Question 4). 14 However, the protocol for this in vivo test would appear to be unsuitable as a screen, since: a) it uses an excessive number of animals (one estimate suggests that 560 animals are required 15 ); and b) it is insensitive, often producing equivocal data. As a result, the test is often bypassed in favour of a two-generation reproductive toxicity test.
The default second species for developmental toxicity testing is the rabbit, although studies in both this species and in rodents are < 87% accurate in predicting human teratogenicity. 16 A recent investigation by ECVAM, involving a review of all the substances listed in the EU New Chemicals Database as tested for developmental toxicity, has revealed that a prevalence for developmental toxicity of < 5% can be expected, since, from 84 (OECD 414) tests on 58 chemicals, only 3 were classified as "harmful to the unborn child (R61 or R63)" (Bremer, S., unpublished communication, 2006) .
After assessing the published summary reports of data on veterinary drug residues in food, which represent a variety of chemical classes, Hurtt et al. 17 suggested a tiered approach for developmental toxicity testing, commencing with the use of rodents (preferably the rat). Further testing in a second species (preferably the rabbit) was only needed in the case of negative or equivocal data.
So far, my conclusions are that: a) in vitro embryotoxicity tests should be used for screening; b) other non-animal methods might also be useful; c) an enhanced one-generation reproductive toxicity test might be sufficient; d) the existing OECD in vivo screening test should not be used; and e) testing should normally be in, or at least be initially confined to, the rat. The question now is how the use of this information could lead to an objective and scientifically justified overall testing strategy (Question 6).
Reproductive toxicity testing, like other toxicity testing, should be applied in the context of an intelligent, integrated strategy, making maximum use of non-animal approaches (previous information, computer prediction, read-across, and in vitro methods, such as the embryotoxicity tests), before resorting to traditional animal testing. Classification and labelling and/or quantitative risk assessment, and any further testing, could be undertaken at various stages. 18 Hopefully, any required animal methods would be based on the use of an enhanced one-generation reproductive toxicity test, following rapid agreement on an appropriate protocol.
The implementation of integrated testing schemes: a) permits chemicals to be screened out at early stages of testing, without using animals (replacement), thereby reducing the time, financial costs and the overall amount of testing (reduction) involved; and b) increases the chance that those chemicals that are tested further will be not be toxic to the animals used (refinement).
Recent work has shown that the predictivity of in vitro embryotoxicity tests can be improved by correcting effective test substance concentrations for bioavailability in vitro and in vivo. 19 In this way, it might even be feasible to use such data for quantitative risk assessment. 20 In conclusion, for scientific, animal welfare and logistical reasons, I strongly urge the adoption of an intelligent integrated testing approach to assessing human reproductive risk from exposure to chemicals in fulfilment of the requirements of the REACH legislation. This should involve nonanimal replacement approaches, and refinement and reduction in any truly essential testing conducted in the rat, rather than the application of a check-list approach focused primarily on traditional animal testing. I hope that these, and other, like-minded, views that are being increasingly expressed, will be taken properly into account by those charged with formally advising the EC on how to implement the REACH system. They should also remember two further facts. Firstly, in view of the potential long delay between exposure and effect in relation to reproductive toxicity, it is most important that any such potential effects of the 10,000 or so existing chemicals which lack data for this endpoint, are identified and quantified as soon as possible. Secondly, it would appear that the number of chemicals which would affect development in humans is likely to be very low in comparison to the number that are positive in animal tests. Thus, much unnecessary and time-consuming testing could be conducted, at great financial cost and requiring very large numbers of animals -without increasing the protection of humans at all. Instead, there is an urgent need for research to provide greater insight into the mechanisms involved in developmental and reproductive toxicity, so that more-relevant and scientifically more-advanced test methods can be devised. 
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